RECRUITING

MEASuRE: Metreleptin Effectiveness And Safety Registry

Talk to us

Conditions

Generalised LipodystrophyPartial LipodystrophyLipodystrophyMetreleptin Registry

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.

Official Title

MEASuRE: Metreleptin Effectiveness And Safety Registry

Quick Facts

Study Start:2016-10-11
Study Completion:2031-10-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02325674

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients treated with metreleptin through commercial supply at the time or before enrolment into registry
  2. * Patients who provide a written consent
  3. * Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Lori Hartnett
CONTACT
+3905212791
clinicaltrials_info@chiesi.com

Principal Investigator

Lori Hartnett
STUDY_DIRECTOR
Amryt Pharmaceuticals DAC

Study Locations (Sites)

University Alabama at Birmingham
Birmingham, Alabama, 40506
United States
City of Hope
Duarte, California, 91010
United States
Atlanta Diabetes Associates
Atlanta, Georgia, 30318
United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
United States
University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas, 66160
United States
Children's Hospital of New Orleans/LSU Health Sciences Center
New Orleans, Louisiana, 70118
United States
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
United States
Nih/Niddk/Deob
Bethesda, Maryland, 20892
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
Childrens Hospital of Michigan
Detroit, Michigan, 48201
United States
Richmond University Medical Centre
Staten Island, New York, 10314
United States
Endocrinology Research Associates
Columbus, Ohio, 43201
United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
UT Southwestern Medical Center
Dallas, Texas, 75390
United States
Seattle Children's Hospital
Seattle, Washington, 98105
United States

Collaborators and Investigators

Sponsor: Aegerion Pharmaceuticals, Inc.

  • Lori Hartnett, STUDY_DIRECTOR, Amryt Pharmaceuticals DAC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-10-11
Study Completion Date2031-10-31

Study Record Updates

Study Start Date2016-10-11
Study Completion Date2031-10-31

Terms related to this study

Keywords Provided by Researchers

  • Lipodystrophy
  • Metreleptin Registry

Additional Relevant MeSH Terms

  • Generalised Lipodystrophy
  • Partial Lipodystrophy